A novel Phase I/IIa theranostic clinical study exploring the safety profile and efficacy of both 99mTc-RHN001 and 188Re-RHN001 in patients with advanced prostate cancer.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 28 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Rhenium-188-RHN-001-Rhine-Pharma (Primary) ; Technetium-99m-RHN-001-Rhine-Pharma (Primary)
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms RHINO Trial

22 Nov 2024 According to Telix Pharmaceuticals Media release, The RHINO Trial has received both ethics and regulatory approval in South Africa and is being run by NuMeRI's CEO and President, Professor Mike Sathekge, and his team.
28 Oct 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com